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Human cytomegalovirus (HCMV) infections of immunocompetent hosts are characterized 
by a dynamic, life-long interaction in which host immune responses, particularly of T cells, 
restrain viral replication and prevent disease but do not eliminate the virus or preclude 
transmission. Because HCMV is among the largest and most complex of known viruses, 
the T cell resources committed to maintaining this balance have never been characterized 
completely. Here, using cytokine flow cytometry and 13,687 overlapping 15mer peptides 
comprising 213 HCMV open reading frames (ORFs), we found that 151 HCMV ORFs were 
immunogenic for CD4
 
 
 
 and/or CD8
 
 
 
 T cells, and that ORF immunogenicity was influenced 
only modestly by ORF expression kinetics and function. We further documented that total 
HCMV-specific T cell responses in seropositive subjects were enormous, comprising on 
average 
 
 
 
10% of both the CD4
 
 
 
 and CD8
 
 
 
 memory compartments in blood, whereas
cross-reactive recognition of HCMV proteins in seronegative individuals was limited to
CD8
 
 
 
 T cells and was rare. These data provide the first glimpse of the total human T cell 
response to a complex infectious agent and will provide insight into the rules governing 
immunodominance and cross-reactivity in complex viral infections of humans.
 
Human cytomegalovirus (HCMV) is a mem-
ber of a distinct, widely distributed subgroup
of 
 
 
 
-herpesviruses that share common growth
properties, characteristic cytopathology, salivary
gland tropism, and a capacity to establish perma-
nent infection (1). A large portion of humanity
harbors this virus; infection rates range from
40% to 
 
 
 
90% depending on socioeconomic
status. For almost all infected persons, both
acute and persistent infection are benign.
However, HCMV can cause severe disease in
the setting of cellular immune deficiency or
immaturity, including transplant recipients, in-
dividuals with late-stage HIV infection, and
congenitally infected neonates (2), and studies
in both humans and animal models have dem-
onstrated a critical role for both CD4
 
 
 
 and
CD8
 
 
 
 T cell immunity in limiting viral replica-
tion and preventing the clinical manifestations of
progressive infection (3–5). Given the capacity
of unrestrained infection to cause disease, the
biology of HCMV infection in immunocom-
petent populations can be conceptualized as an
evolutionarily “negotiated” balance between
viral mechanisms of pathogenesis, persistence,
and immune evasion and the host cellular im-
mune response.
The immunologic basis of this balance has
not been characterized completely. In particu-
lar, the nature and threshold level of HCMV-
specific T cell responses required for long-term
HCMV containment remain to be defined. Such
information would facilitate identification of
highly susceptible individuals and provide a
specific target for immunotherapeutic approaches
designed to establish, maintain, or restore immu-
nologic protection against this virus. Moreover,
recent data closely link HCMV exposure and
expansion of HCMV-specific CD8
 
 
 
 T cells to
senescence of the immune system in the elderly
(6, 7), suggesting that there are clinical conse-
quences to an overly robust HCMV-specific T
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cell response. An obvious prerequisite for a better under-
standing of what constitutes insufficient or excessive
HCMV-specific T cell immunity is the ability to evaluate
the overall HCMV-specific T cell response in infected indi-
viduals. However, the complexity of this virus, which in-
cludes a double-stranded DNA genome encoding 
 
 
 
200
open reading frames (ORFs) for proteins 
 
 
 
80 amino acids in
length (1), has been a major obstacle to the comprehensive
analysis of the HCMV-specific T cell response necessary for
such evaluation.
Previous work by many groups has defined CD4
 
 
 
 and/or
CD8
 
 
 
 T cell responses to whole viral lysates, virally infected
cells, a subset of individual ORFs, and various MHC-
restricted epitopes (8–19), but the extent to which these mea-
surements reflect the overall T cell response to HCMV has not
been determined. To resolve this issue definitively, we selected
the inclusive, empirical approach of synthesizing overlapping
15mer peptides encompassing all 213 known or predicted
HCMV ORFs and applying these peptides in a validated cy-
tokine flow cytometry (CFC) assay to a large cohort of HLA-
disparate, HCMV-seropositive subjects and to a control cohort
of HCMV-naive individuals. These experiments provide the
first complete picture of the structure of the human T cell re-
sponse to a complex, persistent infectious agent, including def-
inition of (a) the frequency and extent to which these HCMV
gene products are recognized by human CD4
 
 
 
 and CD8
 
 
 
 T
cells; (b) the relationship between the immunogenicity of each
gene product and its function, expression kinetics, abundance,
and variability; (c) total HCMV-specific CD4
 
 
 
 and CD8
 
 
 
 re-
sponses in HCMV-infected subjects, and (d) the extent to
which T cells in HCMV-naive individuals are cross-reactive
with HCMV-encoded determinants.
 
RESULTS
Experimental approach to the pan-genomic evaluation of 
HCMV immunogenicity
 
Based on the HCMV sequence information available in June
2000, we synthesized consecutive 15mer peptides, overlap-
ping by 10 amino acids, for 213 predicted HCMV proteins,
including 191 from the HCMV laboratory strain AD169 and
an additional 22 from the Toledo or Towne HCMV strains
(see Materials and methods and Table S1, available at http://
www.jem.org/cgi/content/full/jem.20050882/DC1). These
13,687 peptides were then arranged in ORF-specific mixes
or, for very large ORFs (those yielding 
 
 
 
200 peptides), sub-
ORF mixes. The 232 resulting peptide mixes were used in
individual CFC assays (20), along with AD169 lysate, a neg-
ative control (costimulation alone), and a positive control
(Staphyloccocal enterotoxin B), for a total of at least 235 de-
terminations per subject. These assays were performed on
PBMCs from 33 HCMV-seropositive and 10 HCMV-
seronegative adult subjects who were selected to maximize
ethnic and HLA diversity (Table I). Note that the HCMV-
seropositive cohort includes a heterogeneous sampling of
HLA alleles (15 HLA-A, 26 HLA-B, 13 each HLA-C and
HLA-DRB1, and 5 HLA-DQB1), including most of those
commonly found in most human populations (21). All sub-
jects were healthy volunteers with no HCMV viremia de-
tectable by real-time PCR.
 
Identification of immunogenic HCMV ORFs 
in natural infection
 
Fig. 1 A illustrates a typical analysis of an HCMV-seropositive
subject. CD4
 
 
 
 or CD8
 
 
 
 T cells specifically reactive with
peptides within the peptide mixes respond by induction of
CD69 and 
 
 
 
-IFN. Negative controls indicated the extent of
background activation, and these frequencies were subtracted
from the peptide mix result to provide a net response fre-
quency. Because this background subtraction is subject to sto-
chastic fluctuation, we defined a positive net response as
 
 
 
0.06% for CD4
 
 
 
 T cells and 
 
 
 
0.08% for CD8
 
 
 
 T cells,
based on statistical analysis of the responses of the HCMV-
seronegative cohort (see Materials and methods). Even by
these conservative criteria, the HCMV genome was found to
be remarkably immunogenic for T cells (Fig. 1 B). Of the 213
HCMV ORFs assessed, 151 elicited at least one CD4
 
 
 
 and/
 
Table I.
 
Cohort demographics and HLA types
 
Gender Race Age (yr)
Number 
screened
Number 
enrolled Female Male White
African 
American
Asian 
American Other 19–29 30–39 40–55
HCMV serostatus
 
Positive 58 33 16 17 22 3 5 3 7 12 14
Negative 72 10 5 5 6 0 2 2 3 2 5
 
HLA type Alleles represented in HCMV-seropositive (all) and -seronegative (*) cohorts
 
A 01*, 02*, 03*, 11*, 23*, 24*, 26, 29, 30, 31*, 32, 33, 66*, 68, 74
B 07*, 08*, 13*, 14*, 18*, 27, 35*, 38*, 39, 44*, 46, 47, 49*, 51*, 53, 56*, 57, 58, 59, 60*, 61, 62, 63*, 70, 75, 81
Bw 04*, 06*
Cw 01*, 02, 03*, 04*, 05*, 06, 07*, 08*, 12*, 14, 15*, 16, 18
DRB1 01*, 03*, 04*, 07, 08*, 09*,10, 11*, 12, 13*, 14, 15*, 16
DRB 3/4/5 3*, 4*, 5*
DQA1 01*, 02, 03*, 04*, 05*
DQB1 02*, 03*, 04*, 05*, 06* 
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or CD8
 
 
 
 T cell response. Fig. 1 C shows the rank order of all
ORFs recognized by CD4
 
 
 
 T cells (top) or CD8
 
 
 
 T cells
(bottom) with respect to the frequency of recognition in the
HCMV seropositive cohort. Note that 40 ORFs (19%) were
recognized by CD4
 
 
 
 T cells in at least 4/33 subjects, and five
ORFs (UL55, UL83, UL86, UL99, and UL122) were recog-
nized by more than half of the study subjects. For CD8
 
 
 
 T
cells, 33 ORFs (15.5%) were recognized by four or more sub-
jects, and three ORFs (UL48, UL83, and UL123) were rec-
ognized by more than half the subjects. Although the recogni-
tion hierarchies for CD4
 
 
 
 and CD8
 
 
 
 T cell responses were
different, there was considerable overlap: 8 of the top 15 most
recognized ORFs were common to both lineages (UL55,
UL83, UL122, UL48, UL32, UL123, UL99, and UL82).
Figure 1. Identification of HCMV ORF–specific CD4  and CD8  T 
cell responses in HCMV-seropositive adults. (A) PBMCs from HCMV-
seropositive subject P6 were stimulated with costimulation plus mixtures 
of consecutive, overlapping 15mer peptides comprising complete HCMV 
ORFs (UL36, UL83, and UL122) or large ORF fragments (UL32B, UL55A) or 
with costimulation alone (negative control) and then were examined by 
CFC for their correlated expression of surface CD3 and CD4 and intracellular 
CD69 and  -IFN. The profiles shown were gated on CD3 /CD4  small
lymphocytes (CD4  T cells) or CD3 /CD4  small lymphocytes (CD8  T 
cells), with the responding (CD69 / -IFN ) T cells depicted in bold (% in 
upper right corner of each profile) and the nonresponding T cells in gray. 
The results shown are typical of seropositive donors in which certain ORFs 
generated clusters of responding cells over and above the spontaneous 
activation noted in controls. (B) The pie chart shows the fraction of the 
tested 213 HCMV ORFs that are able to stimulate at least one positive 
CD4  and/or CD8  T cell response (as defined in Materials and methods) 
in 33 HCMV-seropositive donors. (C) The number of times that each 
HCMV ORF is recognized by CD4  T cells (top) or CD8  T cells (bottom) 
in the 33 HCMV-seropositive donors is shown, from the most to least
frequently recognized (note: the CD4 and CD8 analyses are independent, 
reflecting all the responses of a given lineage, irrespective of the
response of the other lineage). 
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T cell recognition of HCMV ORFs in 
HCMV-seronegative subjects
 
T cells from the 10 HCMV-seronegative subjects manifested
a very different reactivity pattern to the HCMV peptide
mixes. For the vast majority of these analyses (2,320/2,320
CD4; 2,313/2,320 CD8), the responses to the HCMV pep-
tide mix were not quantitatively or qualitatively different
from background. However, four HCMV-seronegative sub-
jects demonstrated seven clear-cut, reproducible CD8
 
 
 
 T
cell responses to three HCMV ORF mixes: three subjects
responded to US32, and two each responded to US29 and
UL116 (Fig. 2 A). One of the HCMV-seronegative subjects
with HCMV ORF–specific CD8
 
 
 
 T cell responses (subject
N1) was an identical twin whose HCMV-seropositive sib-
ling was also studied (subject P33). These twins manifested
quantitatively similar responses to US29 and UL116 (Fig. 2
B: twin set A), but the seropositive twin manifested an addi-
tional 19 CD4
 
 
 
 and 27 CD8
 
 
 
 ORF–specific responses. In
contrast, the HCMV ORF–specific response profiles of a
pair of HCMV-seropositive identical twins were strikingly
concordant (twin set B), strongly suggesting that the ability
of the HCMV-seronegative twin of set A to respond to the
two HCMV ORFs resulted from cross-reactive recognition
of HCMV epitopes by memory T cells originating from dis-
tinct (e.g., non-HCMV) antigenic exposures.
 
Viral factors influencing T cell recognition of HCMV ORFs
 
To evaluate the influence of viral gene regulation and func-
tion on T cell recognition of HCMV ORFs, we first classi-
fied the tested ORFs with respect to expression kinetics,
function, and virion localization (Table S1).
 
 
 
We then deter-
mined the relative contribution of each ORF class to the
overall set of HCMV-specific responses in the HCMV-sero-
positive cohort (number of CD4
 
 
 
 or CD8
 
 
 
 responses to a
given ORF class divided by the total number of CD4
 
 
 
 or
CD8
 
 
 
 responses in the 33 HCMV-seropositive subjects). Fi-
nally, we compared this relative contribution of each ORF
class to overall T cell recognition with the representation of
that ORF class in the HCMV genome (Table II). This anal-
ysis demonstrated that immunogenic ORFs span all kinetic
and functional categories and that, in general, the observed
contribution of each ORF class to the total response was
commensurate with the coding space of that ORF class in
the HCMV genome. However, there were several notewor-
thy deviations from this proportional distribution. Immedi-
ate-early (IE) gene products were recognized 2.3- and 3.0-
fold over their representation in the HCMV genome by
CD4
 
 
 
 and CD8
 
 
 
 T cells, respectively. Additionally, the fre-
quencies of CD8
 
 
 
 T cells reactive with IE gene products in
peripheral blood were 2.4- to 4.0- fold higher than those re-
active to gene products of other kinetic classes. Also notable
was the preferential recognition of primary immune evasion
proteins by both CD4
 
 
 
 and CD8
 
 
 
 T cells and of viral tegu-
ment and glycoproteins by CD4
 
 
 
 T cells.
As a group, virion components were recognized only
slightly more frequently than their representation in the ge-
nome by both CD4
 
 
 
 and CD8
 
 
 
 T cells (Table II), but these
proteins vary tremendously in abundance. As shown in Fig.
3 A, there was a significant correlation between the relative
abundance of virion proteins determined by proteomic anal-
ysis (22) and the frequency of ORF recognition by the
CD4
 
 
 
 and CD8
 
 
 
 T cells of HCMV-seropositive individuals
Figure 2. T cell recognition of HCMV ORFs in HCMV-seronegative 
subjects and in identical twins that are concordant or discordant for 
HCMV seroreactivity. (A) CFC was used to assess the CD4  and CD8  T 
cell responses of 10 HCMV-seronegative donors to 15mer peptide mixes 
encompassing all 213 HCMV ORFs. The figure demonstrates the 7 assays 
of 4,640 total performed on these subjects (2,320 each for CD4  and 
CD8  T cell responses)—all CD8 —that gave reproducible clusters of 
responding cells that were clearly distinct from background (n   3 for all 
seven responses, including at least one repeat with CD3 /CD8  gating). 
(B) Two sets of identical twins, one (Twin Set A) discordant for HCMV 
seroreactivity, the other (Twin Set B) concordant positive, were evaluated 
for peripheral blood CD4  and CD8  T cell responses to 213 HCMV ORFs 
by CFC. The figure shows all identified responses (CD4  T cell responses 
in red; CD8  T cell responses in green), presented as memory-corrected
response frequencies. The two responses (UL116 and US29) of the sero-
negative twin of set A (subject N1) were two of the seven cross-reactive 
responses noted in Fig. 2 A. 
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(CD8 
 
 
 
 CD4). We also investigated whether strain-to-
strain variability in HCMV protein sequence affected either
T cell recognition or our ability to identify responses with a
single set of peptides. At the time of this writing, sequence
data for six different HCMV strains—two laboratory strains
(AD169 and Towne) and four clinical strains (Toledo, FIX,
PH, and TR)—were available for 160 ORFs (23). Based on
these data, we classified these ORFs into three sequence
variability categories: high (
 
 
 
80% amino acid identity), in-
termediate (80–95% identity), and low (
 
 
 
95% identity). As
shown in Fig. 3 B, almost all frequently recognized HCMV
proteins were in the low-variability category, and frequency
of recognition declined with increasing sequence heteroge-
neity. Peptide mixes encompassing the most variable HCMV
proteins (
 
 
 
80% identity) were recognized very infrequently,
suggesting that sequence differences between the HCMV
strains infecting our subjects and the reference strains used as
a template for peptide synthesis affected our ability to detect
such responses. However, the influence of this effect on our
overall analysis is probably quite small, because these highly
variable proteins constituted only 8% of the total HCMV
proteins assessed.
 
Characterization of total HCMV-specific T cell responses
 
Given the extraordinary degree of HCMV ORF immunoge-
nicity documented, it is not surprising that, when the individ-
ual ORF-specific responses of seropositive subjects were to-
taled, the overall HCMV-specific responses were complex
and often enormous. As shown in Fig. 4 A, the median total
response frequencies for the overall CD4
 
 
 
 and CD8
 
 
 
 pe-
ripheral blood T cell populations were 4.0% and 4.6% (aver-
age, 5.4% and 7.6%), respectively, corresponding to 9.1% and
10.2% (average, 10.7% and 12.8%), respectively, of the mem-
ory compartment. Ten of 33 HCMV-seropositive subjects
manifested total HCMV-specific CD4
 
  and/or CD8  T
cell responses of  20% of their circulating memory reper-
toire. CD4  and CD8  T cells from HCMV-seropositive
subjects recognized a median of 12 and 8 ORFs, respectively,
but the interindividual heterogeneity was considerable, with
the number of ORF-specific CD4  or CD8  responses per
person ranging from as few as 1 to as many as 39 (Fig. 4 B). If
CD4  and CD8  responses are considered together, we
found that individual subjects recognized between 5 and 55
different HCMV ORFs (median, 21). The average size of the
CD8  ORF-specific responses in the blood memory com-
partment of each individual was approximately twice that of
the CD4  ORF-specific responses overall, and the range of
these averages was significantly larger for the CD8  compart-
ment (Fig. 4, C and D). Moreover, the average size of an
ORF-specific CD4  or CD8  T cell population in blood
was unrelated to the frequency of ORF recognition in the
overall seropositive cohort (Fig. 4 D). Finally, we did not
identify a significant relationship between the total HCMV-
specific responses within the CD4  vs. CD8  memory com-
partments, nor was the total HCMV-specific response found
within either of these compartments significantly linked to
any particular HLA haplotype (Table S2, available at http://
www.jem.org/cgi/content/full/jem.20050882/DC1).
Table II. ORF kinetics and function vs. T cell recognition
CD4  T cells CD8  T cells
Categorya
Number of 
HCMV ORFs 
(% of 213)
Genomic 
coding space
Positive responsesb
(n   499) Ratioc
Average positive
response   SEMd
Positive responsesb
(n   378) Ratioc
Average positive 
response   SEMd
%% %
Kinetics
Immediate-early 8 (3.8) 4.6 10.4** 2.3 0.58   0.09 13.8** 3.0 2.23   0.45
Early 56 (26.3) 29.3 29.5 1.0 0.85   0.11 23.3* 0.8 0.55   0.09
Early-late 41 (19.2) 22.9 19.2 0.8 0.73   0.15 20.9 0.9 0.71   0.09
Late 47 (22.1) 22.3 27.9** 1.3 0.75   0.10 27.5* 1.2 1.35   0.21
Function
Capsid 7 (3.3) 8.1 9.8 1.2 0.79   0.20 9.5 1.2 0.70   0.26
Matrix/tegument 23 (10.8) 17.0 27.1** 1.6 0.74   0.09 20.4 1.2 1.46   0.26
Glycoprotein 19 (8.9) 8.6 13.8** 1.6 1.03   0.19 7.4 0.9 0.50   0.11
DNA/regulatory 23 (10.8) 18.5 15.8 0.9 0.50   0.07 24.6** 1.3 1.42   0.27
Immune evasione 27 (12.7) 10.5 20.0** 1.9 0.82   0.11 18.0** 1.7 1.25   0.24
Localization
Dense bodies 17 (8.0) 17.0 27.0** 1.6 0.88   0.09 22.4* 1.3 1.16   0.17
Virion 60 (28.2) 43.7 55.3** 1.3 0.84   0.08 50.0* 1.1 1.13   0.13
aSee Table SI for specific ORF assignments to each category.
bp-value from comparison of percentage of genomic coding space vs. percentage of positive response values:  0.05 (*) or  0.005 (**).
cRatio: percentage of positive responses/percentage of genomic coding space.
dPercentage of peripheral blood memory compartment.
eORFs implicated in immune evasion that are not essential for optimal in vitro growth (may overlap with other functional categories).ANALYSIS OF TOTAL HCMV-SPECIFIC T CELL RESPONSES | Sylwester et al. 678
It is clear from these data that a single ORF-specific T
cell response, or even several of these responses, will not be
representative of the overall status of an individual’s HCMV-
specific T cell response. We thus sought to determine the
minimal combination of ORF-specific responses that would
reliably predict a subject’s total HCMV-specific response.
The most successful strategy for this prediction was based on
the ranking of ORFs with respect to their total cumulative
CD4  or CD8  T cell responses in the HCMV-seroposi-
tive cohort (Table S3, available at http://www.jem.org/cgi/
content/full/jem.20050882/DC1) and then comparing by
regression analysis the total CD4  and CD8  T cell re-
sponses to 213 ORFs with the summed responses of the top
1, 2, 3, 4, 5, 6 . . . 212 ORFs using this ranking system. As
shown in Fig. 5 A, despite the variable sizes of these ORFs,
the sequential addition of the next-ranked ORF resulted in a
fairly linear accumulation of peptides. Fig. 5 B demonstrates
how the slope of these regression lines increased with the in-
clusion of additional ORFs. A perfect correlation is reflected
by a slope of 1, and slopes  1 reflect the relative fraction of
the total available information that is captured with each
analysis. Most relevant to our purpose is the Pearson correla-
tion coefficient, which reflects how well each subtotal analy-
sis correlates with the total analysis. Note in Fig. 5 C that the
Figure 3. Determinants of T cell recognition of HCMV ORFs: abun-
dance of ORF products in virions and ORF variability among different 
HCMV strains. (A) The relative abundance of the 25 HCMV proteins found 
in highly purified HCMV virions, as determined by proteomic analysis (22), 
is plotted against the frequency of recognition of the corresponding ORF 
peptide mixes by CD4  and CD8  T cells in the cohort of 33 HCMV-
seropositive donors. Note that although virion protein abundance correlates 
positively with both CD4  and CD8  ORF recognition frequencies, the 
strength (correlation coefficient, R) and statistical significance (p-value) of 
this association is considerably stronger for CD8  T cell responses. (B) To 
determine the impact of HCMV ORF sequence variability on the measure-
ment of T cell immunogenicity of these ORFs, we compared sequence 
information for the 160 HCMV ORFs that have been sequenced in six 
different HCMV strains (AD169, Toledo, Towne, FIX, PH, and TR) and divided 
these ORFs into three categories: high variability ( 80% amino acid identity; 
13 ORFs), intermediate variability (80–95% identity; 36 ORFs), and low 
variability ( 95% identity, 111 ORFs). The pie charts show the relative 
fraction of the ORFs within each of these categories that are frequently 
recognized by either CD4  or CD8  T cells or both ( 4/33 donors; red),
infrequently recognized (1–4 donors; blue), or not recognized at all (gray). 
The statistical significance of the differences in frequency of T cell recog-
nition among three groups of ORFs (high, intermediate, and low variability) 
was determined by chi square analysis with the p-values between each 
pair of groups shown. The p-value for the overall strength of the association 
between ORF amino acid sequence variability and T cell recognition 
frequencies was  0.0001.JEM VOL. 202, September 5, 2005 679
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increase in this coefficient with inclusion of additional ORFs
was neither linear nor similar for CD4  and CD8  re-
sponses, reflecting the documented differences in the size
and variability of ORF-specific CD4  vs. CD8  responses.
Achieving a correlation coefficient of 0.9 required analysis of
the top 15 ORFs for CD8  responses (1,518 total peptides)
but only the top 6 ORFs for CD4  responses (860 pep-
tides). Fig. 5, D and E shows the actual regression analysis
comparing the summed responses of these numbers of
ORFs/peptides with the total responses for CD8  and
CD4  T cells, respectively. It is noteworthy that CD4  re-
sponses to whole HCMV lysates (Fig. 5 F) also correlated
Figure 4. Characterization of total HCMV-specific T cell responses 
in seropositive subjects. (A) For each seropositive and seronegative 
donor, all positive peripheral blood responses to 213 HCMV ORFs were 
summed (  response frequencies) to determine the total HCMV-specific 
response within the overall or memory CD4  and CD8  peripheral
blood T cell populations. The horizontal lines and accompanying arrows 
and percentages indicate the median total response for the 10 seronegative 
or 33 seropositive donors. Note that the total   HCMV CD4  T cell 
responses was zero for all 10 seronegative donors. As indicated in Fig. 2, 
the total   HCMV CD8  T cell responses was positive for 4/10 donors,
but the median of this distribution remained zero. (B) The number of 
ORFs recognized by the CD4  or CD8  T cells of each HCMV-seropositive 
donor is shown. The horizontal line indicates the median value of the 
overall population of 33 donors. (C) For each HCMV-seropositive individual, 
the total HCMV ORF–specific CD4  or CD8  T cell responses in the
memory compartment (  response frequencies) were divided by the 
number of responses contributing to that total to arrive at the average 
size of HCMV ORF–specific responses in each donor (as a fraction of the 
peripheral blood memory population). The figure shows the distribution 
of these average sizes with the horizontal line indicating the median 
value of the overall population of 33 seropositive donors. (D) The figure 
shows the average size ( SEM) of the memory-corrected CD4  or CD8  
T cell response to each individual ORF in the individuals that manifested 
a positive response to that ORF. Only ORFs with responses in at least 4 of 
33 donors are shown in descending order with respect to ORF recognition 
frequency (see Fig. 1).ANALYSIS OF TOTAL HCMV-SPECIFIC T CELL RESPONSES | Sylwester et al. 680
significantly with total ORF responses, but both the slope
and correlation coefficient value of this relationship were
significantly less than observed for the summation of the top
six CD4  ORFs.
DISCUSSION
In this report, we provide the first comprehensive assessment
of human CD4  and CD8  memory T cell responses to the
overall HCMV proteome. We demonstrate that normal,
HCMV-exposed individuals devote a median of 9.1% and
10.2% of their circulating CD4  and CD8  memory T cell
repertoires, respectively, to this virus, recognizing a median
of 21 different HCMV ORFs by CD4  T cells, CD8  T
cells, or both. With the exception of infrequent CD8  T cell
cross-reactivity, HCMV-seronegative, presumably unex-
posed, subjects lack these responses, highlighting the enor-
mous, permanent influence HCMV infection has on the
memory T cell compartment. Moreover, our data may un-
der-represent the actual extent and complexity of the
HCMV-specific T cell responses in our subjects because (a)
 -IFN production is not an all-inclusive marker of memory
T cell responsiveness (9, 24); (b) 15mer peptides are not opti-
mal agonists for MHC class I-restricted responses (20, 25); (c)
some epitopes may be excluded using a 10–amino acid over-
lap between the consecutive peptides of our ORF mixes; and
(d) strain-specific sequences, recently described ORFs, and
ORFs  80 amino acids (26, 27) were not evaluated.
Although there are few comparative data for pan-pro-
teome immunogenicity analysis of other human viral infec-
tions, previous reports assessing T cell responses to viral ly-
sates, infected cells, or immunodominant epitopes strongly
suggest that the frequencies of HCMV-specific T cells in
healthy subjects considerably exceed those observed for
other common viruses, including measles, mumps, influenza,
adenovirus, poxvirus, and even other persistent Herpes fam-
ily viruses (e.g., Herpes simplex, Herpes zoster [9, 11, 15,
28–30]) and are comparable with frequencies of HIV-spe-
cific T cells in active HIV infection (31). The properties of
HCMV that engender such large, sustained T cell responses
in the absence of overtly active infection have not been es-
tablished definitively, but the observation that the high-fre-
quency T cell responses characteristic of CMV infection in
mice, nonhuman primates, and humans evolve during the
first year of infection ([12, 32–34] and L. Picker, unpub-
lished observations) suggests that the nature of antigen deliv-
ery to the immune system during primary infection is a criti-
Figure 5. Modeling of the total HCMV-specific T cell response for 
practical clinical evaluation. (A–C) To ascertain a practical surrogate 
for the   response frequencies to 213 HCMV ORFs, we rank ordered the 
HCMV ORFs by their total response in the 33 seropositive donors (e.g.,   
response frequencies in the overall cohort; see Table S3 for ranking) and 
then performed linear regression analysis comparing the   response fre-
quencies of the 213 HCMV ORFs with the   response frequencies of the 
top 1 ORF, the top 2 ORFs, the top 3, top 4, and so on. The x-axis of these 
graphs indicates the increasing number of ORFs added to each analysis (of 
213 total, only 1–50 are shown). In plot A, the number of peptides added 
to the analysis with each added ORF is shown (of 13,687 total). Plot B 
shows the slope of the regression line as a function of increasing ORFs. 
Plot D shows the relationship between increasing ORFs and the Pearson 
correlation coefficient. The dotted lines in plot D indicate the minimum 
number of ORFs required to achieve a correlation coefficient of 0.9; in 
plots A and B, the corresponding number of peptides and regression slope 
are indicated. (D and E) Regression analysis comparing   response fre-
quencies using 213 HCMV ORFs with the   response frequencies of the 
top 15 ORFs for CD8  responses and the top 6 ORFs for CD4  responses. 
(F) Regression analysis comparing   CD4  response frequencies using all 
213 HCMV ORFs with the CD4  response frequencies obtained using 
whole HCMV lysates as the stimulating antigen.JEM VOL. 202, September 5, 2005 681
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cal parameter. The relatively slow, prolonged, and limited
viral replication of CMV primary infection may simply allow
more efficient recruitment of CMV-specific T cells into the
memory compartment than do the antigen-presentation pat-
terns of other viruses.
The extent to which these relatively high frequencies of
HCMV-specific T cells are required for protection against
progressive HCMV infection and disease remains unclear.
The rarity of HCMV disease in immunocompetent individ-
uals suggests that even within the lowest decile of HCMV-
specific responsiveness (frequencies in blood about 10-fold
lower than the median), most exposed individuals have suf-
ficient responses to protect them from HCMV disease
throughout their lifetime. At the other end of the response
spectrum, our observation that  30% of adult subjects have
HCMV-specific populations comprising  20% of their cir-
culating CD4  and/or CD8  memory T cell repertoire
suggests that HCMV-specific T cell responsiveness might be
excessive in some individuals, perhaps with detrimental clin-
ical effects. Indeed, current thinking on the pathophysiology
of immune senescence supports this notion (6, 7). Elderly in-
dividuals with this condition demonstrate high-frequency,
oligoclonal CD8  effector-memory T cell responses to
HCMV epitopes with concomitant loss of both naive and
non–HCMV-specific memory CD8  T cells, and it has been
hypothesized that expanded HCMV-specific T cell popula-
tions crowd out or otherwise dysregulate immune responses
to other potential pathogens (7, 35–38). We did not include
elderly subjects in this study but note that it is easy to envi-
sion that small changes in the relative survival of CMV-spe-
cific vs. non–CMV-specific CD8  memory T cells over a
period of years could lead eventually to an overwhelming
preponderance of CMV-specific cells and consequent im-
mune dysfunction.
The strikingly high representation of HCMV-reactive
memory T cells in HCMV-seropositive subjects contrasts
sharply with the almost nonexistent HCMV reactivity of T
cells from HCMV-seronegative subjects. We found no evi-
dence of CD4  T cell reactivity with HCMV epitopes in
HCMV-seronegative subjects, extending previous work that
demonstrated a lack of reactivity to HCMV whole viral
preparations in such subjects (9, 39). With respect to CD8 
T cell reactivity, we identified an average of 0.7 HCMV
ORF–specific responses, comprising 0.39% of memory T
cells in blood, per seronegative subject—a total that was  3%
of the total HCMV-specific CD8  T cell reactivity of
HCMV-seropositive subjects. These responses focused on
only three HCMV ORFs (UL116, US29, US32), suggesting
a very limited set of potentially cross-reactive epitopes
among the many hundreds of total HCMV epitopes. Exper-
imental studies in mice have suggested that cross-reactivity is
common and plays a major role in molding the memory T
cell repertoire and in determining the outcome of pathogen
encounters (40). Anecdotal observations have demonstrated
the existence of such CD8  T cell cross-reactivity in hu-
mans (40, 41), but the extent to which cross-reactivity con-
tributes to the configuration of the overall human memory
T cell repertoire has remained unclear. As the first compre-
hensive assessment of this question in humans, our data sug-
gest that cross-reactivity is rare to nonexistent for CD4  T
cells and is uncommon for CD8  T cells. Therefore, cross-
reactivity does not seem to be a major determinant of the
human memory T cell repertoire. However, this finding
does not mean that CD8  T cell cross-reactivity is clinically
insignificant. With respect to HCMV, it would be of partic-
ular interest to determine whether preexistent cross-reactive
responses to UL116, US29, or US32 affect the course of pri-
mary HCMV infection.
Previous work on HCMV-specific T cell immunity has
often focused on a very restricted group of HCMV ORFs,
principally UL83 (pp65) and UL123 (IE-1), with the under-
lying assumption that such responses are immunodominant
and representative of the total response to this virus. A recent
study examining responses to epitopes predicted by HLA-
binding algorithms has cast some doubt on this assumption,
suggesting that CD8  T cell recognition is broader than an-
ticipated, including responses to functionally and kinetically
diverse ORFs (14). This study extends these observations,
definitively demonstrating that T cell recognition of HCMV
is complex, often very broad, and poorly approximated by
responses to any one or two HCMV ORFs. We found that
151 (70%) of the 213 HCMV ORFs examined were immu-
nogenic for CD4  T cells, CD8  T cells, or both, with 40
ORFs for CD4  T cells and 33 for CD8  T cells recog-
nized by at least 12% of subjects. Significantly, of the 62
ORFs that failed to generate a response in our seropositive
subjects, 26 were on a list of 34 ORFs that newer annotation
approaches indicate have low coding potential and therefore
are unlikely to represent bona fide HCMV ORFs (27).
Thus, our 151 immunogenic ORFs may in fact derive from
a total of only 187, yielding an actual ORF immunogenicity
rate for T cells of 86%. Whether the remaining 14% of
ORFs truly lack immunogenicity remains an open question.
It is possible that further screening of more subjects or the
use of more sensitive assays would demonstrate recognition
of all expressed HCMV ORFs; on the other hand, restricted
expression, processing restrictions, and/or a paucity of HLA-
presentable epitopes might efficiently prevent immunoge-
nicity of a small minority of HCMV-encoded proteins.
Immunogenic ORFs were found in all kinetic and func-
tional categories of HCMV proteins, and, in general, the fre-
quency with which T cells recognized these ORF categories
was in proportion to their representation in the HCMV pro-
teome. However, for some ORF classes, the frequency of
immune recognition did show statistically significant devia-
tion from what would be expected if epitope selection was
random (Table II), most notably, the  3-fold preferential
recognition of IE gene products by CD8  T cells. Because
expression of HCMV-encoded MHC class 1 down-regula-
tory genes initiates in the IE phase (42), it is possible that re-
duced MHC class I expression in early- to late-stage infected
cells might have impeded CD8  T cell recognition of earlyANALYSIS OF TOTAL HCMV-SPECIFIC T CELL RESPONSES | Sylwester et al. 682
and late HCMV proteins, leading to preferential recognition
of IE proteins. However, 86% of HCMV ORF–specific
CD8  T cell responses were not directed at IE gene products
(Table II), confirming recent data by Manley et al. (43) sug-
gesting that MHC class I down-regulation is not a major
impediment to afferent CD8  T cell recognition (perhaps be-
cause uninfected DCs have a major role in the cross-
presentation of HCMV epitopes during CD8  T cell re-
sponse development). Indirect antigen presentation is the
norm for MHC class II–restricted responses, and the prefer-
ential recognition of IE genes by CD4  T cells also suggests
that factors other than MHC down-regulation contributed
to the preferential recognition of IE gene products. One po-
tential contributor to differential HCMV protein recogni-
tion is simply the relative expression level of these proteins
during in vivo infection. Although the overall representation
of HCMV proteins during in vivo infection is unknown,
our observation that protein abundance in virions was signif-
icantly associated with the frequency of protein recognition
by both CD4  and CD8  T cells supports the importance of
this factor. Finally, it is noteworthy that HCMV genes that
have a primary function in immune evasion are preferen-
tially immunogenic (Table II). The retention of such genes
in the HCMV genome is clear evidence that the likely
“cost” of these proteins to viral fitness in terms of enhanced
immunogenicity is more than compensated by their immune
modulatory activity.
The extraordinary complexity of HCMV-specific T cell
responses complicates efforts to understand the basis of the
HCMV-immune balance and, in clinical practice, to deter-
mine the thresholds that define the boundary between
controlled vs. progressive HCMV infection in immune-
compromised subjects and between normal and excessive
HCMV-specific immunity in the elderly. Total HCMV-spe-
cific CD4  and CD8  T cell frequencies are a fundamental
measure of the HCMV-specific cellular immune response
and serve as an appropriate starting point for determining
these thresholds in clinical cohorts. Qualitative aspects of the
total responses would almost certainly contribute to protec-
tion as well, but these characteristics must still be considered
in the context of the quantitative response. Because it is im-
practical to perform the comprehensive 213-ORF analysis of
this report in a clinical setting, we sought to identify a limited
combination of ORF-specific responses that, when added
together, would efficiently approximate the total response.
For CD4  T cell responses, this goal was achieved using only
the six most immunogenic ORFs (UL55, UL83, UL86,
UL99, UL153, and UL32), requiring 860 15mer peptides.
Notably, responses with crude HCMV viral lysates also cor-
related closely with the total response, but the correlation
coefficient was lower (0.79), and the slope of the correlation
line (a measure of the total information captured by the anal-
ysis) was considerably less (0.24 vs. 0.42, respectively). Mod-
eling the total HCMV-specific CD8  T cell response was
more difficult. Whole HCMV lysates are poorly stimulatory
for MHC class I–mediated responses (20), and such responses
do not correlate at all with pan-ORF responses (unpublished
data). Moreover, because HCMV ORF–specific CD8  T
cell responses were more variable than their CD4  counter-
parts, we needed to sum the response of the top 15 ORFs
(UL123, UL83, UL122, UL28, UL48, US3, UL151, UL82,
UL94, US29, UL99, UL103, US32, US24, and UL36; 1,518
peptides) to achieve an acceptable correlation coefficient.
Because UL83 and UL99 are common to both the CD4 
and CD8  ORF lists, analysis of 19 ORF peptide mixes
(2,231 total peptides) would provide a very good approxima-
tion of an individual’s total HCMV-specific T cell response.
Using CFC and judicious construction of the peptide mixes
(180–200 peptides per test), such analysis could be performed
with 15   106 PBMCs, a scope well within the range of
practical clinical application.
MATERIALS AND METHODS
Subjects. This study was approved by the Institutional Review Board of
Oregon Health and Science University. 130 healthy adult human volunteers
(all subjects recruited after obtaining written informed consent) were
screened for seroreactivity to HCMV using the CMVScan passive latex ag-
glutination test (Becton Dickinson). Of 58 seropositive subjects, 26 were se-
lected for inclusion in the study group based on maximizing the HLA and
ethnic diversity. An additional seven separately identified seropositive sub-
jects were added to the study population (for a total of 33), four to increase
the breadth of HLA allele and ethnic representation and three as part of iden-
tical twin sets (one set concordant for HCMV seroreactivity and the other
discordant). Nine seronegative subjects were selected randomly as controls,
with the CMV-seronegative twin from the discordant twin set added as the
tenth control. In keeping with previous reports (9, 39), CFC assays assessing
CD4  T cell responses to whole HCMV lysates were positive (with net re-
sponse frequencies  0.3%) in all 33 seropositive subjects and were negative
in all 10 seronegative subjects ( 0.02%). Real-time PCR analysis of HCMV
DNA in PBMCs was negative in all studied subjects. All subjects were HLA
genotyped by the Puget Sound Blood Center in Seattle, WA.
Cell preparation, antigen stimulation, and staining. Citrated periph-
eral blood was collected from each donor and processed into PBMCs, as pre-
viously described (8). These PBMCs (minimum 500   106 for each subject)
were cryopreserved in 10% DMSO in FCS at 20   106 cells/ml using a
Forma Scientific Model 7404 CryoPlus 3 cell freezer (Forma Scientific, Inc.).
For each analysis, PBMC aliquots were rapidly thawed at 37oC, diluted with
RPMI-1640 medium with 10% heat-inactivated FCS, washed once, and re-
suspended at 2   106 cells in 0.5 ml media in 12   75–mm polystyrene
tubes (Becton Dickinson). An additional 0.5 ml containing 1  g each of the
costimulatory mAbs CD28 and CD49d (BD Biosciences) and no antigen, ti-
tered whole HCMV lysates (AD169 strain, Microbix Biosystems, Inc.), 0.2
 g Staphyloccocal enterotoxin B, or HCMV ORF peptide mixes was added
to each tube. These cultures were incubated at a 5o slant from horizontal at
37oC in a humidified 5% CO2 atmosphere for 6 hr with the final 5 hr in-
cluding 10  g/ml of the secretion inhibitor Brefeldin A (Sigma-Aldrich).
After incubation, cells were harvested with Dulbecco’s PBS containing 0.5%
BSA and 0.1% sodium azide (dPBS/BSA) and were washed before incuba-
tion in titered PerCP-Cy5.5–conjugated CD3 mAb (clone SK7, BD Bio-
sciences) for 30 min at room temperature. Cells then were washed once in
dPBS/BSA, were fixed and permeabilized with FACSLysing solution (BD
Biosciences), and then, after being washed twice in dPBS/BSA, were incu-
bated with FITC–anti-IFN-  (clone 25723.11), PE-CD69 (clone L78), and
APC-CD4 (clone SK3, all mAbs from BD Biosciences). After 30 min incu-
bation at RT, cells were washed twice with cold PBS/BSA, resuspended in
1% paraformaldehyde in dPBS, and then stored at 4oC until analysis. Each
PBMC sample was also assessed for the fraction of memory T cells within the
CD4  and CD8  T cell populations by cell surface staining with mAbs (a)JEM VOL. 202, September 5, 2005 683
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FITC-CD45RO/PE-CD27/PerCP-CD8/APC-CD95 and (b) FITC-
CD45RO/PE-CD27/PerCP-CD4/APC-CD95 (all from BD Biosciences).
Preparation of HCMV ORF peptide mixes. As of June 2000, the ini-
tiation of this project, the only annotated, complete genetic sequence for
HCMV was for the laboratory strain AD169, and this sequence served as
the starting point for our peptide synthesis, providing 191 ORFs, including
several alternative splice variants. AD169 had been shown to be missing nu-
merous ORFs compared with other CMV strains (44), so we added added
19 ORFs from Toledo and 3 ORFs from Towne strains to our list for a to-
tal of 213 ORFs (Table S1). Sequence data were obtained from GenBank/
EMBL/DDBJ (protein database) site and from the SWISS-PROT database
via the EXPASY (expert protein analysis system) site (see Table S1 for ac-
cession numbers). ORFs were annotated with regard to expression kinetics
and function as described in Table S1. Consecutive 15mer peptides, over-
lapping by 10 amino acids, were synthesized for each ORF by Mimotopes
Pty., Ltd., using solid-phase peptide synthesis methods, employing an Fmoc
synthesis strategy, with simultaneous side-chain deprotection and cleavage
techniques incorporating scavengers (to maximize purity and yield), to lib-
erate the peptides from solid phase. Peptides with free acid C-termini and
free-amine N-termini were lyophilized in 96-tube racks, each with two
controls that were analyzed for quality control by mass spectrometry,
HPLC, and amino acid analysis. Lyophilized peptides were reconstituted in
5-40% acetic acid in acetonitrile. Peptides associated with each of the 213
ORFs were pooled, lyophilized, and reconstituted in pure DMSO, so that
each peptide was at a minimum concentration of 0.5mg/ml. 4  l of these
preparations was added to PBMC so that final stimulatory peptide concen-
trations were always  2  g/ml per peptide.
Flow cytometry and data analysis. Six-parameter flow cytometric
analysis was performed on a two-laser FACSCalibur instrument (BD Bio-
sciences) using CellQuest v3.3 software (BD Biosciences). List-mode multi-
parameter data files (each file with forward scatter, orthogonal scatter, and
four-fluorescent parameters) were analyzed using the PAINT-A-GATE
Plus software program (BD Biosciences), as described (8). Files were gated
on CD3 , CD4  and separately on CD3 , CD4  small lymphocytes with
responding populations defined as CD69 /IFN-  . Approximately 20%
of positive CD4  T cell responses were re-examined using a panel includ-
ing a CD8 mAb, and in all cases the CD3 , CD4  responses were con-
firmed as CD8 . A minimum of 20,000 gated events and background reac-
tivity   0.06% (e.g., in the absence of peptides) was required for an
acceptable data point. Analyses not meeting these criteria were repeated. To
establish a precise definition of positive responses, we analyzed the net (e.g.,
minus background) CD4  and CD8  T cell responses to the 213 HCMV
ORFs in the HCMV-seronegative subjects. With the exception of seven
CD8  responses (which were excluded from this analysis; see Results), the
flow cytometric profiles of these analyses lacked clear-cut response clusters,
and net response frequencies of both the CD4  and CD8  analyses formed
a normal distribution with a mean of 0, and 4 SD equaling 0.06% for CD4 
analyses and 0.08% for CD8  analyses. These 4-SD frequencies were
adopted as our cut-off for a positive response to rule out stringently any
spurious responses in our overall data analysis. Thus, net response frequen-
cies of  0.06% for CD4  T cells and  0.08% for CD8  T cells were
counted as zero response. To ensure accuracy, we repeated all analyses
within 0.02% of the cut-off, and if two consecutive repeat analyses showed
net response frequencies above the cut-off, the mean of these responses was
counted. When ORFs were analyzed in parts, a positive response by these
criteria by any ORF sub-mix constituted an ORF-specific response, and if
one or more such positive responses was identified, these responses were
summed to calculate a total ORF-specific response frequency. For memory
correction, total ORF-specific response frequencies were divided by the
fraction of the CD4  or CD8  T cells with a memory phenotype, as previ-
ously described (8). Note that the term “memory” is used to denote the
overall compartment of previously activated, peripheral T cells, including
“effector” or “effector memory” populations.
Statistical analyses. Linear regression analysis was used to determine the
correlation between (a) the response profiles of identical twins, (b) ORF rec-
ognition vs. ORF abundance, (c) CD4 vs. CD8 responses, and (d)  213
ORF responses to  1 212 ORF responses. ANOVA was used to assess the
association between the average positive response and ORF kinetics/func-
tion. A one-sample test for a proportion was used to compare the frequency
among positive responses with the expected frequency from the genome
coding space. Because we performed multiple tests within each class, the
Bonferroni adjustment was used to control the overall type 1 error of 5%.
Thus, a p-value   0.05/K is considered significant, where K is the number
of categories in each class. A chi-square test was used to assess an association
between the recognition frequencies and ORF variability. Statistical tests
were performed with Statistical Analysis System Version 9.0 or Statview 5.0
(SAS Institute).
Online supplemental materials.  Table S1 provides the amino acid se-
quences of, and the functional and kinetic annotations for, the HCMV
ORFs studied in this report, as well as the original source material for this
information. Table S2 provides demographic information, HLA types, and a
complete listing of the HCMV ORFs recognized by CD4  and CD8  T
cells (listed separately) for each of the HCMV-seropositive subjects. Table
S3 provides the complete database for the response modeling shown in Fig.
5. All HCMV ORFs were rank ordered with respect to their total immu-
nogenicity in the HCMV-seropositive cohort (  of the total response fre-
quencies in the memory compartments of all 33 seropositive subjects), and
then the total response of each subject to all 213 tested ORFs ( 213 ORF
response frequency) was sequentially compared with the top ORF, top 2
ORFs, top 3 ORFs, and so forth ( 1   212 ORF response frequencies).
The correlation coefficients, the slope of the regression lines, and the 95%
confidence limits of these statistical analyses are indicated, as well the num-
ber of peptides corresponding to each analysis. Online supplemental mate-
rial available at http://www.jem.org/cgi/content/full/jem.20050882/DC1.
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